REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 218 filers reported holding REATA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,950,000 | +8.1% | 12,500 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $1,804,000 | -29.4% | 12,500 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,555,000 | +184.2% | 12,500 | +11.6% | 0.00% | +200.0% |
| Q3 2019 | $899,000 | +38.1% | 11,200 | +62.3% | 0.00% | 0.0% |
| Q2 2019 | $651,000 | +90.4% | 6,900 | +72.5% | 0.00% | – |
| Q1 2019 | $342,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $110,053,269 | 27.64% |
| Ghost Tree Capital, LLC | 500,000 | $18,995,000 | 8.11% |
| First Light Asset Management, LLC | 2,062,453 | $78,352,589 | 7.27% |
| Boxer Capital, LLC | 1,230,004 | $46,727,852 | 2.46% |
| Sofinnova Investments, Inc. | 992,029 | $37,687,182 | 2.24% |
| Tri Locum Partners LP | 141,466 | $5,374,000 | 2.17% |
| MPM BioImpact LLC | 194,181 | $7,376,936 | 1.91% |
| Ikarian Capital, LLC | 201,200 | $7,643,588 | 1.84% |
| KRS Capital Management, LLC | 28,141 | $1,069,077 | 1.46% |
| EMERALD ADVISERS, LLC | 679,772 | $25,824,538 | 1.25% |